Dividends never go out of style, but some dividend stocks can. That's how some investors might feel about (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) these days. Both companies have generally maintained solid dividend programs, but right now they both face issues with slow or nonexistent revenue and earnings growth.

Pfizer and Bristol Myers Squibb have severely underperformed the S 500 over the past 12 months, and if these issues persist, things could get worse. Let's find out whether it's too late to buy shares of these passive income stocks.

Two years ago, Pfizer became the first company in the biopharma industry to hit $100 billion in annual sales. Things have changed dramatically since then. The drugmaker's COVID-19 portfolio, which fueled its record-breaking sales run, lost steam as the pandemic receded. Last year, revenue and earnings dropped off a cliff. This could affect its dividend program.

Continue reading

Source Fool.com